Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.
Posted 16 February 2012 | By Alexander Gaffney, RAC
Senator Kay Hagan (R-NC) introduced a bill in the Senate on 15 February that would accelerate the review and approval of treatments for rare, neglected or serious diseases.
Hagan's bill, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, would also make a number of changes at the US Food and Drug Administration (FDA), including :
Hagan noted that the bill intends to transform "FDA's internal processes to ensure more consistency and clarity," but does not contain any government funding to accomplish these tasks.
"This legislation creates a consistent process and a clear and effective pathway at FDA that will encourage the development of innovative treatments for patients otherwise dependent on the uncertainty of medical breakthroughs," said Hagan in a press release.
The bill already has the support of the Biotechnology Industry Association (BIO), the National Organization for Rare Disorders (NORD), Friends of Cancer Research (FOCR).
Tags: Accelerated, TREAT Act, Hagan, Legislation, Applications, Latest News, Mission, Senate, Bill, Congress
Regulatory Focus newsletters
All the biggest regulatory news and happenings.